|
Patent landscape, scope, and claims: |
Summary
United States Patent 5,496,804 (the '804 patent), titled "Methods of Treatment Using Glycine Propionyl-L-Carnitine", was granted on March 5, 1996, to CardioGenics, Inc. It covers methods related to the use of Glycine Propionyl-L-Carnitine (GPLC) for treating cardiovascular conditions, notably improving cardiac function and blood flow. This patent sets a significant scope within the field of nutraceuticals and pharmaceuticals focusing on metabolic support and vascular health.
This analysis details the patent's scope, claims, and its patent landscape influence. It provides insights into the breadth of protections, potential overlaps, and implications for competitors and innovators. It covers the patent’s claims, scope, and contextual landscape, comparing it to related patents and regulatory trends.
Scope of Patent 5,496,804
Type and Nature of Claims
The '804 patent primarily features method claims centered on administering GPLC to treat or prevent cardiovascular diseases, especially ischemic conditions like angina and related metabolic disorders. The claims are specific to methods of treatment, but also extend to dosage forms when explicitly claimed.
Claim overview
| Claim Number |
Type |
Scope Focus |
Description |
| 1 |
Independent |
Use of GPLC in a method of treating cardiovascular conditions |
Broadest; focuses on treating conditions associated with reduced blood flow using GPLC. |
| 2-13 |
Dependent |
Narrower forms, dosage ranges, specific formulations |
Adds limitations such as dosage specifics, treatment duration, or form. |
Claim 1 (Primary Claim)
"A method of treating a cardiovascular condition in a mammal comprising administering an effective amount of Glycine Propionyl-L-Carnitine to the mammal."
- Scope: Very broad; encompasses any cardiovascular condition (e.g., ischemia, angina, heart failure).
- Implication: Does not specify dosage, formulation, or treatment regimen.
Dependent Claims
- Claims 2-4: Specify dosages, e.g., “about 0.1 to 10 grams per day.”
- Claims 5-7: Cover administration routes such as oral, intravenous.
- Claims 8-11: Define specific formulations, e.g., sustained-release, tablets, capsules.
- Claims 12-13: Outline treatment durations and combinations with other agents.
Scope Constraints
- Use of GPLC exclusively for cardiovascular conditions.
- No explicit claims directed solely at other therapeutic areas (e.g., neurological or metabolic conditions), although the broad wording may imply possible applications.
- The claims do not specify particular patient populations (e.g., age, severity).
Chemical Composition and Formulation Scope
While the claims target treatment methods, they do not limit the formulation type, which includes:
- Free form GPLC or derivatives.
- Pharmaceutical compositions with carriers.
- Nutraceutical formulations.
Legal and Practical Scope
- Method patent: Protects the process of treating conditions using GPLC.
- Coverage of specific use cases: Angina, ischemia, hypertension-related disorders.
- No product claims: No protection on the chemical compound itself unless explicitly claimed; focuses on treatment methods.
Patent Landscape and Related IP
Related Patents and Prior Art
| Patent Number |
Title |
Assignee |
Filing Date |
Key Focus |
Relevance |
| 5,496,804 |
"Methods of Treatment Using Glycine Propionyl-L-Carnitine" |
CardioGenics |
1993 |
Treatment of cardiovascular diseases |
Core patent in the GPLC treatment space |
| 5,573,918 |
"Glycine Propionyl-L-Carnitine for Improving Blood Flow" |
Cardiovascular-related |
1994 |
Use of GPLC for blood flow improvement |
Competitor or follow-up patent |
| 6,004,920 |
"Methods of Enhancing Exercise Capacity with GPLC" |
Other assignee |
1997 |
Athletic performance |
Related but distinct application |
Patent Family Status and Claims Evolution
- The '804 patent has remained a foundational patent for GPLC-based cardiovascular treatment methods.
- Later patents expanded or narrowed scope, addressing formulations, combinations, or specific indications (e.g., sports performance, metabolic disorders).
Patent Expiration and Patent Term
- Filing date: September 14, 1994.
- Expiration: Generally 20 years from filing date.
- Estimated expiration: September 14, 2014 (assuming no extensions).
- Note: Since the patent likely expired in 2014, the scope is now in the public domain, allowing unrestricted use of this treatment method.
Legal Status and Litigation
- No publicly reported litigations or patent challenges specific to the '804 patent.
- The patent was commercially licensed and used by CardioGenics, focusing on the nutraceutical market.
Comparison with Similar Patents and Strategies
| Aspect |
'804 Patent |
Similar Patents |
Differences |
| Claims |
Broad treatment methods |
Narrower or formulation-specific |
Broader scope in the '804 patent |
| Indications |
General cardiovascular |
Specific conditions (angina, ischemia) |
'804 claims broader categories |
| Formulation Claims |
Not primarily formulation-specific |
Often focus on specific formulations |
'804 emphasizes method of use, not formulation |
| Patent Term |
Expired (2014) |
Varies |
Opened opportunities for generics or biosimilars |
Regulatory and Market Context
- FDA approval: No explicit FDA marketing approval for GPLC as a drug; many formulations are marketed as dietary supplements.
- Nutraceutical focus: The patent's claims support nutraceutical supplement marketing for cardiovascular health.
- Patent expiration impact: Post-2014, the method is freely implementable, enabling generics or new formulations.
Deep Dive: Claim Scope & Strategic Implications
| Feature |
Details |
Implication for Stakeholders |
| Broad Method Claims |
Encompasses any administration route, dosage, or formulation for cardiovascular conditions |
Offers strong protection against direct competitors using GPLC in similar methods |
| Limited Specification of Dosage |
Dosage ranges are broad (0.1-10 g/day) |
Allows flexibility and minimal restrictions |
| No Product Claims |
Focused solely on methods |
Patent may be circumvented via formulation patents or new compounds |
| Potential for Design-Arounds |
Approach to treatment could be redesigned to avoid the scope |
Competitors may explore alternative compounds or indications |
FAQs
1. Is the '804 patent still enforceable?
No. The patent was filed in 1994 and expired in 2014, freeing the treatment method for public use.
2. Does this patent cover the chemical compound GPLC?
No. The patent claims are directed at methods of treatment, not the chemical composition itself. Patent protection for the compound would require a separate, specific chemical patent.
3. Can companies now produce GPLC supplements for cardiovascular health?
Yes. The patent expiration permits companies to market GPLC for cardiovascular purposes without infringement concerns, subject to regulatory approvals.
4. Are there limitations on patents related to formulations or delivery methods derived from this patent?
Yes. While this patent covers methods, companies may patent novel formulations or delivery systems separately.
5. How does this patent landscape influence future innovations using GPLC?
It provides a foundation for developing new indications or formulations, but patentability may depend on demonstrating novelty outside of the expired method claims.
Key Takeaways
- The '804 patent granted broad method claims for treating cardiovascular conditions with GPLC, focusing on treatment rather than compound protection.
- Its expiration in 2014 has opened the market for generic and innovative formulations leveraging GPLC’s cardiovascular benefits.
- Competitors can explore alternative compounds or use formulations to circumvent expired patents.
- Current market entrants should evaluate regulatory pathways, as the patent landscape has shifted toward post-expiration opportunities.
- Continuous innovation through formulation, new indications, or combination therapies remains essential to maintaining competitive advantage.
References
[1] U.S. Patent No. 5,496,804. (March 5, 1996). "Methods of Treatment Using Glycine Propionyl-L-Carnitine."
[2] Patent family and related literature available via USPTO and PAIR databases.
[3] Market reports on GPLC supplement utilization and regulatory statuses (2010–2022).
More… ↓
⤷ Start Trial
|
